BeiGene to Present Clinical Data on Anti-PD-1 Antibody Tislelizumab at the European Society for Medical Oncology Immuno-Oncol...
December 10 2018 - 6:05AM
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage
biopharmaceutical company focused on developing and commercializing
innovative molecularly-targeted and immuno-oncology drugs for the
treatment of cancer, today announced it will present data on its
investigational anti-PD-1 antibody tislelizumab at the European
Society for Medical Oncology (ESMO) Immuno-Oncology Congress, being
held December 13-16 in Geneva, Switzerland.
Mini Oral Presentation:
Title: |
A Phase 1A/1B
trial of Tislelizumab, an Anti-PD-1 Antibody (Ab), in Patients
(Pts) With Advanced Solid Tumors |
Presentation #: |
70O |
Session: |
Mini Oral
Session (ID37) |
Location: |
Room A,
Geneva Palexpo |
Date: |
Saturday,
December 15 |
Time: |
08:30
CET |
Presenter: |
Chia-Chi
Lin, M.D., Ph.D., National Taiwan University Hospital |
Poster Presentation:
Title: |
Tislelizumab, an
Anti-PD-1 Antibody, in Patients With Urothelial Carcinoma (UC):
Results From an Ongoing Phase 1/2 Study |
Presentation #: |
76P |
Session: |
Poster
display session (ID 9) |
Location: |
Foyer,
Geneva Palexpo |
Date: |
Friday,
December 14 |
Time: |
12:30
CET |
Lead Author: |
Shahneen
Sandhu, M.D., Peter MacCallum Cancer Centre-East Melbourne, East
Melbourne, Victoria, Australia |
About Tislelizumab
Tislelizumab (BGB-A317) is an investigational
humanized IgG4 anti–PD-1 monoclonal antibody specifically designed
to minimize binding to FcγR on macrophages. In pre-clinical
studies, binding to FcγR on macrophages has been shown to
compromise the anti-tumor activity of PD-1 antibodies through
activation of antibody-dependent macrophage-mediated killing of T
effector cells.
Discovered by BeiGene scientists,
tislelizumab is being developed as a monotherapy and in combination
with other therapies for the treatment of a broad array of both
solid tumor and hematologic cancers. The new drug application (NDA)
for tislelizumab in China for patients with R/R cHL has
been accepted by the China National Medical Products
Administration (NMPA, formerly known as CFDA) and granted priority
review status. BeiGene and Celgene
Corporation have a global strategic collaboration for the
development of tislelizumab in solid tumors in the United
States, Europe, Japan and the rest of world
outside Asia.
About BeiGeneBeiGene is a global,
commercial-stage, research-based biotechnology company focused on
molecularly-targeted and immuno-oncology cancer therapeutics. With
a team of over 1,700 employees in China, the United States,
Australia and Switzerland, BeiGene is advancing a pipeline
consisting of novel oral small molecules and monoclonal antibodies
for cancer. BeiGene is also working to create combination solutions
aimed to have both a meaningful and lasting impact on cancer
patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound
paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in
China under a license from Celgene Corporation.1
Investor
Contact |
Media
Contact |
Craig West |
Liza Heapes |
+1 857-302-5189 |
+ 1 857-302-5663 |
ir@beigene.com |
media@beigene.com |
_____________________________
1 ABRAXANE®, REVLIMID®, and VIDAZA® are
registered trademarks of Celgene Corporation.
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Apr 2023 to Apr 2024